BlackRock Inc. Has $15.40 Million Position in SIGA Technologies, Inc. (SIGA)

BlackRock Inc. raised its position in shares of SIGA Technologies, Inc. (OTCMKTS:SIGA) by 35,114.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,593,187 shares of the biotechnology company’s stock after buying an additional 2,585,823 shares during the quarter. BlackRock Inc. owned about 3.28% of SIGA Technologies worth $15,403,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wells Fargo & Company MN acquired a new stake in SIGA Technologies during the first quarter valued at approximately $104,000. Ladenburg Thalmann Financial Services Inc. acquired a new stake in SIGA Technologies during the first quarter valued at approximately $137,000. Atlantic Trust Group LLC acquired a new stake in SIGA Technologies during the first quarter valued at approximately $254,000. Rhumbline Advisers acquired a new stake in SIGA Technologies during the second quarter valued at approximately $282,000. Finally, Strs Ohio acquired a new stake in SIGA Technologies during the second quarter valued at approximately $295,000. Hedge funds and other institutional investors own 6.66% of the company’s stock.

Shares of SIGA Technologies stock opened at $4.87 on Tuesday. The company has a debt-to-equity ratio of -0.22, a current ratio of 5.49 and a quick ratio of 5.05. SIGA Technologies, Inc. has a twelve month low of $3.90 and a twelve month high of $8.47.

SIGA Technologies (OTCMKTS:SIGA) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.09) earnings per share for the quarter. The firm had revenue of $2.66 million during the quarter.

SIGA Technologies Company Profile

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding SIGA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SIGA Technologies, Inc. (OTCMKTS:SIGA).

Institutional Ownership by Quarter for SIGA Technologies (OTCMKTS:SIGA)

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply